ArticleFrontiers in oncology2022
Increased PD-1
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 12 citations in OpenAlex.
- Immune Checkpoints in Leukaemia as Gatekeepers of Immuno-Modulation.Immunology · 2026Review
- Dynamics and immunological signature of γδ T cells following antiretroviral therapy initiation in acute HIV-1 Infection.Frontiers in immunology · 2025Article
- Immunosuppressive cells in acute myeloid leukemia: mechanisms and therapeutic target.Frontiers in immunology · 2025Review
- Heterogeneity of γδ T-cell subsets and their clinical correlation in patients with AML.Frontiers in immunology · 2025Article
- γδ T cells and the PD-1/PD-L1 axis: a love-hate relationship in the tumor microenvironment.Journal of translational medicine · 2024Review
- Immune Regulatory Networks and Therapy of γδ T Cells in Liver Cancer: Recent Trends and Advancements.Journal of clinical and translational hepatology · 2024Review
- Higher TIGIT+ γδ TFrontiers in immunology · 2024Article
- Anti-PD-1 antibody armored γδ T cells enhance anti-tumor efficacy in ovarian cancer.Signal transduction and targeted therapy · 2023Article
- T cells in health and disease.Signal transduction and targeted therapy · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Problems: γδ T cells are essential for anti-leukemia function in immunotherapy, however, γδ T cells have different functional subsets, including regulatory cell subsets expressing the Foxp3. Whether they are correlated with immune-checkpoint mediated T cell immune dysfunction remains unknown in patients with acute myeloid leukemia (AML). Methods: In this study, we used RNA-seq data from 167 patients in TCGA dataset to analyze the correlation between Results: We found that Conclusion: A significant increase in the PD-1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.